论文信息 - Glimepiride and Serum Adiponectin Level in Type 2 Diabetic Subjects: Response to Yoshioka, Yoshida, and Yoshikawa

Glimepiride and Serum Adiponectin Level in Type 2 Diabetic Subjects: Response to Yoshioka, Yoshida, and Yoshikawa

We thank Yoshioka, Yoshida, and Yoshikawa for their comments on our article (1) in this issue of Diabetes Care (2). We reported that serum adiponectin concentration increased after 3 months’ glimepiride treatment in type 2 diabetic patients (1). They indicated that baseline values of serum adiponectin (22.1 ± 2.7 μg/ml, mean ± SE) seem to be higher than those expected from subjects with greater BMI (26.5 ± 0.9 kg/m2) and homeostasis model assessment of insulin resistance (5.0 ± 0.8) levels. First, we must apologize …

[1] T. Yoshikawa,et al. Glimepiride and serum adiponectin level in type 2 diabetic subjects: response to Nagasaka et al. , 2003, Diabetes care.

[2] S. Ishibashi,et al. Effect of glimepiride on serum adiponectin level in subjects with type 2 diabetes. , 2003, Diabetes care.

[3] M. Matsuda,et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. , 2003, Diabetes.

[4] K. Shimamoto,et al. Blockade of the Renin-Angiotensin System Increases Adiponectin Concentrations in Patients With Essential Hypertension , 2003, Hypertension.

[5] Toshio Hayashi,et al. Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects. , 2003, Diabetes care.

[6] M. Matsuda,et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. , 2001, Diabetes.